Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,

Accordion Pill for proprietary compound achieves in-vitro specifications Moving into clinical pharmacokinetic (PK) study in 2019 JERUSALEM , Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Accordion Pill™ developed for a

Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2018 and

JERUSALEM , Nov. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in November.  H.C. Wainwright 2018 Annual Israel Conference Date: November 11, 2018

On Track to Report Topline Data in Mid-2019 for Potential New Baseline Levodopa Treatment JERUSALEM , Oct. 22, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the completion of patient enrollment in the Company's pivotal Phase 3 clinical trial

JERUSALEM , Sept. 25, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming

JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences.  Oppenheimer 2018 Fall Summit - Focused on Specialty Pharma and Rare Disease Date:

Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the

Former LabCorp CFO Brings Wealth of Financial Experience JERUSALEM, June 29, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors.  Mr.

JERUSALEM , May 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City . Jeffrey A.